Physician profile
Lance Mckay Harmon
NPI 1811912157
$3,657.73
in general payments reported to CMS, 2019-2025
26 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $629 · 2021: $809 · 2022: $378 · 2023: $403 · 2024: $571 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $498.32 | 2019-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.55 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $406.35 | 2020-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $370.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $313.08 | 2019-2023 | Xarelto |
| Pfizer INC. | $205.50 | 2019-2025 | |
| Abbvie INC. | $203.64 | 2021-2025 | |
| Novo Nordisk INC | $188.99 | 2020-2025 | Ozempic, Rybelsus |
| Amgen INC. | $164.24 | 2019-2025 | Evenity, Prolia, Prolia |
| Amarin Pharma, INC. | $132.79 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $107.58 | 2020-2024 | Gardasil, Vaxelis, Capvaxive |
| Glaxosmithkline, LLC. | $75.94 | 2020-2024 | Shingrix, Bexsero, Arexvy |
| Insulet Corporation | $71.41 | 2023-2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.83 | 2022-2025 | Xifaxan, Trulance |
| Allergan, INC. | $53.43 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $53.20 | 2022-2023 | Quviviq |
| Lundbeck LLC | $46.21 | 2021-2023 | Vyepti |
| Mylan Specialty L.P. | $43.45 | 2021 | |
| Exact Sciences Corporation | $39.29 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $33.47 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $32.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.95 | 2023 | |
| Dexcom, INC. | $16.12 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $14.01 | 2024 | Intracept |
| Medtronic, INC. | $13.79 | 2023 | Minimed 780g |
| Gilead Sciences, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.